moxifloxacin has been researched along with Bacterial Pneumonia in 82 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (54.88) | 29.6817 |
| 2010's | 26 (31.71) | 24.3611 |
| 2020's | 11 (13.41) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, E; Das, AF; File, TM; Gelone, SP; Goldberg, L; Heinrich, S; Moran, GJ; Patel, P; Paukner, S; Sandrock, C; Schranz, J; Vidal, JE; Waites, KB | 1 |
| Anyfantakis, D; Makrakis, G | 1 |
| Cheng, L; Dai, Q; Ding, J; Feng, W; Li, X; Pu, W; Sun, F; Wang, J; Wang, Y; Yang, B; Yuan, Q; Zhang, D; Zhang, H | 1 |
| Cammarata, S; Keedy, K; Lawrence, L; McCurdy, S; Nenninger, A; Quintas, M; Sheets, A | 2 |
| Donato, A; Powell, D | 1 |
| Bozkaya, D; Lodise, TP; Massey, J; Spargo, A; Tillotson, GS | 1 |
| Lai, CC; Tang, HJ; Wang, JH | 1 |
| Chen, JY; Li, X; Tong, B; Wang, JY | 1 |
| Curran, M; Das, AF; Eckburg, PB; Garrity-Ryan, L; Kirsch, C; Manley, A; McGovern, PC; Steenbergen, JN; Torres, A; Tzanis, E | 1 |
| LaPensee, K; Lodise, TP; Mistry, R; Young, K | 1 |
| Alexander, E; Das, AF; File, TM; Goldberg, L; Moran, GJ; Paukner, S; Sandrock, C | 1 |
| Chitra, S; McGovern, P; Pai, MP; Wilcox, M | 1 |
| Hong, J; Reyes, HA; Sueldo, C; Witsch, J | 1 |
| Adamzik, M; Asmussen, S; Karlik, J; Peters, J; Rahmel, T; Steinmann, J | 1 |
| Den Beste, KA; Okeke, C | 1 |
| Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Plamthottam, S; Tullius, MV; Wang, R; Yu, CJ; Zink, JI | 1 |
| Das, A; File, TM; Gasink, LB; Gelone, SP; Goldberg, L; Paukner, S; Saviski, J; Seltzer, E; Sweeney, C; Talbot, GH; Wicha, WW | 1 |
| Das, AF; Eckburg, PB; Garrity-Ryan, L; Gonong, JR; Kirsch, C; Loh, E; Madej, A; Manley, A; McGovern, PC; Mitha, I; Nseir, W; Popescu, M; Steenbergen, JN; Stets, R; Tzanis, E | 1 |
| Chitra, S; Curran, M; Kirsch, C; Manley, A; McGovern, PC; Noble, R; Ramirez, JA; Tzanis, E | 1 |
| Chao, CM; Lai, CC; Lin, SH | 1 |
| Goldstein, RC; Husk, G; Jodlowski, T; Mildvan, D; Perlman, DC; Ruhe, JJ | 1 |
| Bals, R; Beisswenger, C; Bischoff, M; Honecker, A; Kamyschnikow, A; Tschernig, T | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Alder, J; Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R | 1 |
| Antonovsky, Y; Barrera, CM; Clark, K; Das, AF; Doreski, PA; Fernandes, P; Flores-Figueroa, J; Horwith, G; Jamieson, B; Karimjee, N; Keedy, K; Metev, H; Mitha, I; Molina, JM; Mykietiuk, A; Nitu, MF; Oldach, D; Rewerska, B; Rowe, BH; Scott, D; Sheets, A; Tanaseanu, CM; Van Rensburg, DJ | 1 |
| Deng, H; Li, J; Li, Q; Wen, R | 1 |
| Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V | 1 |
| Decramer, M; Simoens, S | 1 |
| Anzueto, A; Miravitlles, M | 1 |
| Enoch, DA; Ludlam, HA | 1 |
| Gupta, M; Janmeja, AK; Mohapatra, PR | 1 |
| Kawai, A; Nakamura, A; Takakuwa, O; Torii, M; Yamamoto, T | 1 |
| Simoens, S | 1 |
| An, MM; Cao, YB; Gao, PH; Jiang, YY; Shen, H; Zou, Z | 1 |
| Arvis, P; Fritsch, A; Garau, J; Read, RC | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Ewig, S; Hecker, H; Marre, R; Suttorp, N; Welte, T | 1 |
| Fukano, H; Hara, H; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Moriya, O; Niki, Y; Okimoto, N; Yoneyama, H; Yoshida, K | 1 |
| Arvis, P; Choudhri, SH; Haverstock, D; Kruesmann, F; Miravitlles, M; Perroncel, R | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Bai, N; Cai, Y; Chen, LA; Cui, JC; Liang, BB; Liu, YN; Sun, CG; Wang, R; Yu, XH; Yuan, X; Zhao, TM | 1 |
| Asano, K; Betsuyaku, T; Fujiwara, H; Hasegawa, N; Miyata, J; Miyazaki, M; Naoki, K; Ohkusu, K; Sayama, K; Tasaka, S; Yoshida, S | 1 |
| Duprat-Lomon, I; Lamping, DL; Marquis, P; Marrel, A; Sagnier, PP; Schroter, S | 1 |
| Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP | 1 |
| de la Roza, C; Jardim, JR; Miravitlles, M; Obispo, E; Rico, G; Urueta, J; Wolff, M | 1 |
| Allewelt, M; Burkhardt, O; Lode, H; Pletz, MW; Welte, T | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Buchheidt, D; Hofheinz, R; Hummel, M | 1 |
| Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T | 1 |
| Arvis, P; Breilh, D; Djabarouti, S; Gordien, JB; Jougon, J; Landreau, V; Saux, MC; Velly, JF; Xuereb, F | 1 |
| Martinez, FJ | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Beecroft, MD; Herman-Gnjidic, Z; Marrie, TJ | 1 |
| Choudhri, S; Fogarty, CM; Hamed, K; Katz, E; Larsen, LS; Song, J | 1 |
| Choudhri, SH; Church, D; Haverstock, D; Hoeffken, G; Jackson, P; Larsen, LS; Peloquin, S; Talan, D | 1 |
| Kovács, G; Máthé, A; Tóth, K | 1 |
| Brambilla, C; Garre, M; Paganin, F; Portier, H; Poubeau, P; Zuck, P | 1 |
| Ethaković-Rode, O; Kuzman, I; Puljiz, I | 1 |
| Morovic, M | 1 |
| Bauer, TT; Petermann, W; Reimnitz, P; Schürmann, D; Welte, T | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Leenders, AC | 1 |
| Krause, R; Laferl, H; Széll, M; Wenisch, C | 1 |
| Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J | 1 |
| Bassetti, M; DI Biagio, A; Righi, E; Rosso, R; Tosi, C; Viscoli, C | 1 |
| Barth, J; Beckmann, H; Höffken, G; Rubinstein, E | 1 |
| Ferrara, AM | 1 |
| Decramer, M; Martin, M; Moore, L; Quilici, S; Simoens, S | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Lindsell, C; Ryan, RJ; Sheehan, P | 1 |
| Church, D; Haverstock, D; Patel, T; Pearl, J; Williams, J | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Ball, P | 1 |
| Fukano, H; Matsushima, T; Miyashita, N; Niki, Y; Yoshida, K | 1 |
| Bobbaers, H; Collins, O; Finch, R; Hoeffken, G; Izquierdo, JL; Kubin, R; McGivern, J; Nikolaides, P; Ogundare, F; Raz, R; Schürmann, D; Zuck, P | 1 |
12 review(s) available for moxifloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Community-Acquired Infections; Costs and Cost Analysis; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis | 2008 |
Moxifloxacin: a respiratory fluoroquinolone.
Topics: Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis | 2008 |
Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
Topics: Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Doxycycline; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; United Kingdom | 2008 |
Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Topics: Anti-Bacterial Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Cost-Benefit Analysis; Diarrhea; Drug Resistance, Microbial; Economics, Pharmaceutical; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Practice Guidelines as Topic; Quinolines | 2009 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bronchitis, Chronic; Color; Disease Progression; Dyspnea; Female; Fluoroquinolones; Gentian Violet; Humans; Male; Moxifloxacin; Multicenter Studies as Topic; Phenazines; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic; Sex Factors; Sputum | 2012 |
Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2012 |
Bacillus cereus necrotizing pneumonia in a patient with nephrotic syndrome.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Aza Compounds; Bacillus cereus; Biopsy, Needle; Bronchoalveolar Lavage Fluid; Clindamycin; Drug Therapy, Combination; Fluoroquinolones; Follow-Up Studies; Gram-Positive Bacterial Infections; Humans; Immunocompromised Host; Immunohistochemistry; Male; Meropenem; Moxifloxacin; Necrosis; Nephrotic Syndrome; Pneumonia, Bacterial; Quinolines; Radiography, Thoracic; Risk Assessment; Severity of Illness Index; Thienamycins; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
[Role of moxifloxacin in the treatment of community-acquired pneumonia].
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionnaires' Disease; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Radiography; Treatment Outcome | 2004 |
A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
Topics: Aged; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2007 |
33 trial(s) available for moxifloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Topics: Adult; Bacteria; Coinfection; Community-Acquired Infections; Diterpenes; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates | 2022 |
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionella pneumophila; Macrolides; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Bacterial; Streptococcus pneumoniae; Young Adult | 2020 |
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diterpenes; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Streptococcus pneumoniae; Taiwan; Thioglycolates; Treatment Outcome | 2020 |
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2021 |
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Comorbidity; Diterpenes; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates; United States; Young Adult | 2021 |
Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Community-Acquired Infections; Drug Dosage Calculations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Safety; Tetracyclines; Treatment Outcome | 2021 |
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Diterpenes; Double-Blind Method; Female; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pleuromutilins; Pneumonia, Bacterial; Polycyclic Compounds; Randomized Controlled Trials as Topic; Thioglycolates | 2019 |
Omadacycline for Community-Acquired Bacterial Pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Infusions, Intravenous; Intention to Treat Analysis; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2019 |
Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Approval; Humans; Internationality; Moxifloxacin; Pneumonia, Bacterial; Predictive Value of Tests; Tetracyclines | 2019 |
Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Sputum; Treatment Outcome | 2016 |
Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Europe; Female; Fluoroquinolones; Humans; Latin America; Macrolides; Male; Middle Aged; Moxifloxacin; North America; Pneumonia, Bacterial; South Africa; Triazoles; Young Adult | 2016 |
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Treatment Outcome; Triazoles | 2016 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Topics: Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Bacteria; Cohort Studies; Community-Acquired Infections; Computer Simulation; Female; Fluoroquinolones; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Sputum; Streptococcus pneumoniae; Treatment Outcome | 2011 |
The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Psychometrics; Quality Assurance, Health Care; Quinolines; Surveys and Questionnaires | 2002 |
[A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Latin America; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
Topics: Administration, Oral; Adult; Antibiotic Prophylaxis; Aza Compounds; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infusions, Intravenous; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Postoperative Complications; Prospective Studies; Quinolines; Reference Values; Risk Factors; Tissue Distribution; Treatment Outcome | 2003 |
Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2004 |
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ceftriaxone; Community-Acquired Infections; Constipation; Drug Therapy, Combination; Emergency Medical Services; Female; Fluoroquinolones; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Nausea; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety; Time Factors; Treatment Outcome | 2004 |
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Roxithromycin | 2005 |
Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Child; Clarithromycin; Coxiella burnetii; Doxycycline; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Q Fever; Quinolines; Treatment Outcome | 2005 |
Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Hospitalization; Humans; Injections, Intravenous; Male; Moxifloxacin; Parenteral Nutrition; Pneumonia, Bacterial; Prospective Studies; Quinolines; Remission Induction; Time Factors | 2005 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Treatment Failure | 2006 |
Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefoperazone; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2006 |
A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Cefuroxime; Cross Infection; Drug Therapy, Combination; Endpoint Determination; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2007 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Treatment Outcome | 2000 |
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Fluoroquinolones; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Moxifloxacin; Nasopharynx; Pneumonia, Bacterial; Quinolines | 2000 |
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |
38 other study(ies) available for moxifloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
R on T Phenomenon and Long QTc Syndrome due to Moxifloxacin in a Healthy Female.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged; Moxifloxacin; Pneumonia, Bacterial | 2019 |
Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles.
Topics: A549 Cells; Animals; Anti-Bacterial Agents; Cyclodextrins; Delayed-Action Preparations; Drug Delivery Systems; Female; Humans; Lung; Mice; Moxifloxacin; Nanoparticles; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; RAW 264.7 Cells; Reactive Oxygen Species | 2019 |
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Klebsiella pneumoniae; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2020 |
In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose.
Topics: Adult; Community-Acquired Infections; Diterpenes; Humans; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates | 2020 |
The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Costs; Fluoroquinolones; Humans; Models, Economic; Moxifloxacin; Outpatients; Pneumonia, Bacterial | 2020 |
Epileptic Seizure after Use of Moxifloxacin in Man with Legionella longbeachae Pneumonia.
Topics: China; Epilepsy; Humans; Legionella longbeachae; Legionellosis; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Seizures | 2020 |
Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Clostridium Infections; Community-Acquired Infections; Hospitalization; Humans; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2021 |
Posterior reversible encephalopathy in an adult patient with poststreptococcal glomerulonephritis.
Topics: Adult; Anti-Bacterial Agents; Brain; Diagnosis, Differential; Fluoroquinolones; Glomerulonephritis; Humans; Magnetic Resonance Imaging; Male; Moxifloxacin; Pneumonia, Bacterial; Posterior Leukoencephalopathy Syndrome; Streptococcal Infections | 2017 |
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; beta-Lactams; Bilirubin; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Respiratory Distress Syndrome; Retrospective Studies | 2017 |
Trabeculotomy ab interno with Trabectome as surgical management for systemic fluoroquinolone-induced pigmentary glaucoma: A case report.
Topics: Anti-Bacterial Agents; Cataract Extraction; Eye Pain; Female; Fluoroquinolones; Glaucoma, Open-Angle; Humans; Middle Aged; Moxifloxacin; Ocular Hypertension; Photophobia; Pneumonia, Bacterial; Trabeculectomy | 2017 |
Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Francisella tularensis; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Moxifloxacin; Nanoparticles; Pneumonia, Bacterial; Tularemia | 2019 |
Abdominal wall hematoma and hemoperitoneum in an individual with concomitant use of warfarin and moxifloxacin.
Topics: Abdominal Wall; Aged; Anti-Bacterial Agents; Anticoagulants; Aza Compounds; Blood Coagulation Tests; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; Heart Valve Prosthesis; Hematoma; Hemoperitoneum; Humans; Mitral Valve Insufficiency; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Thromboembolism; Tomography, X-Ray Computed; Warfarin | 2013 |
Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bacteria; Ceftriaxone; Cohort Studies; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Young Adult | 2014 |
Moxifloxacin modulates inflammation during murine pneumonia.
Topics: Animals; Anti-Bacterial Agents; Fluoroquinolones; Immunity, Cellular; Inflammation; Lung; Mice; Mice, Inbred C57BL; Moxifloxacin; Pneumonia, Bacterial | 2014 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
[A case of Legionella pneumonia with multiple organ failure].
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Legionella; Legionnaires' Disease; Male; Middle Aged; Moxifloxacin; Multiple Organ Failure; Pneumonia, Bacterial | 2016 |
Moxifloxacin monotherapy in severe pneumonia: do we really need it?
Topics: Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
[Successful treatment of Legionella pneumonia with moxifloxacin in a hemodialysis patient].
Topics: Aged; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Legionnaires' Disease; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Renal Dialysis | 2009 |
Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionella; Legionellosis; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluoroquinolones; France; Germany; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2003 |
Beau's lines in a patient treated with moxifloxacin for anaerobic pulmonary infection.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Fluoroquinolones; Follow-Up Studies; Humans; Male; Middle Aged; Moxifloxacin; Nail Diseases; Pneumonia, Bacterial; Quinolines; Risk Assessment; Treatment Outcome | 2003 |
Severe Chlamydia pneumoniae infection in a patient with mild neutropenia during treatment of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Female; Fluoroquinolones; Hodgkin Disease; Humans; Imipenem; Immunocompromised Host; Moxifloxacin; Neutropenia; Pneumonia, Bacterial; Quinolines; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin; Vincristine | 2004 |
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
[Antibiotic therapy of respiratory tract infections. Rapid and good effectiveness].
Topics: Aza Compounds; Community-Acquired Infections; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2004 |
Cure of Q fever pneumonia with moxifloxacin: case report.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Coxiella burnetii; Fluoroquinolones; Humans; Male; Moxifloxacin; Pneumonia, Bacterial; Q Fever; Quinolines; Treatment Outcome | 2005 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Tularemia | 2006 |
Treatment of hospitalized patients with community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Hospitalization; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2006 |
Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.
Topics: Adult; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; HIV Infections; Hospitalization; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2007 |
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; Cefuroxime; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
Fluoroquinolone resistance during 2000-2005: an observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Utilization; Enterobacter aerogenes; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pharmacy Service, Hospital; Pneumonia, Bacterial; Quinolines | 2008 |
Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis; Chronic Disease; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2000 |
[One year moxifloxacin. Still effective in the respiratory tract].
Topics: Anti-Infective Agents; Aza Compounds; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2001 |
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydia; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |